The Viva CRT-P features Medtronic-exclusive AdaptivCRT algorithm, which maintains normal heart rhythms and automatically adjusts to the patient’s needs.
Medtronic noted that AdaptivCRT algorithm is the only one demonstrated to improve heart failure patients’ response to the therapy and reduce the risk of atrial fibrillation compared to conventional biventricular therapy.
In addition, Viva CRT-P includes diagnostics tools such as OptiVol Fluid Status Monitoring and Cardiac Compass Report, which offers insight into patients’ physiological condition.
Medtronic heart failure vice-president and general manager and cardiac rhythm and heart failure management business medical director Dr David Steinhaus said the firm aims to help people living with heart failure by making cardiac resynchronization therapy even better through research and improved therapies.
"The addition of Viva CRT-P to our U.S. portfolio reinforces our commitment to making CRT treatment even more powerful by improving care for patients, reducing complications and ultimately reducing costs," Steinhaus added.
